Glenn Dale

New Capabilities

As of May 2026: Overseeing BV100 clinical program

No genuinely new class of antibiotic has reached patients since 1987, and in the nearly four decades since, bacteria have steadily evolved resistance to existing drugs. Carbapenem-resistant Acinetobacter baumannii—a hospital-acquired pathogen that kills up to 60 percent of ventilated pneumonia patients—is at the top of the WHO's list of critical-priority threats. On March 16, 2026, Swiss biotech BioVersys received FDA clearance to enroll American patients in a Phase 3 pivotal trial of BV100, which reduced 28-day mortality by half in earlier testing.

Updated May 30